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Huanjie Shao, PhD,* Haikuo Tang, MD, PhD,*§ Oreste E. Salavaggione, MD,* Chunrong Yu, PhD,*
Bonnie Hylander, PhD,† Wei Tan, MA,‡ Elizabeth Repasky, PhD,† Alex A. Adjei, MD, PhD,* and
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Background: The secreted protein acidic and rich in cysteine
(SPARC) is a matricellular glycoprotein that is produced by tumor
and/or neighboring stroma. SPARC expression is thought to facili-
tate the intracellular accumulation of nanoparticle albumin-bound
paclitaxel (nab-paclitaxel, abraxane [ABX]). Gene hypermethyl-
ation is a common mechanism for loss of SPARC expression in
non-small cell lung cancer (NSCLC). We aim to demonstrate the
role of SPARC expression as biomarker for treatment selection
using ABX in NSCLC and to evaluate the presence of synergistic
antitumor effect when a demethylating agent is combined with
ABX.
Methods: We analyzed the SPARC messenger RNA expression and
SPARC gene methylation status in 13 NSCLC cell lines and 22
minimally passaged patient-derived (PD) NSCLC tumors using
real-time (RT) polymerase chain reaction. The effect of ABX on
tumor growth was compared with cremophor-solubilized paclitaxel
(taxol) in severe combined immunodeficiency mice bearing
SPARC-positive PD xenografts. The effect of pretreatment with a
demethylating agent, 5-Aza-2-deoxycytidine (DEC) in SPARC-
negative tumors was assessed.
Results: SPARC expression was weak to absent in 62% of estab-
lished NSCLC cell lines and 68% of PD NSCLC tumor xenografts.
SPARC expression could be up-regulated/restored by DEC treatment
in both SPARC-negative cell lines and PD xenografts in vitro and in
vivo. ABX demonstrated better antitumor efficacy than equitoxic
dose of taxol in SPARC-expressing xenografts and some SPARC-
negative xenografts. At equimolar doses in vitro, there was similar
increased cytotoxicity on DEC pretreatment with either ABX or
taxol in SPARC-negative cell lines. At equitoxic doses, there was
similar additive antitumor activity of DEC with either ABX or taxol
in SPARC-negative PD xenografts.
Conclusion: Endogenous SPARC status is somewhat uncorrelated
with response to ABX in NSCLC. The greater antitumor effect of
ABX compared with equitoxic dose of taxol observed in SPARC-
expressing NSCLC tumors can also be seen in some SPARC-
negative tumors. DEC pretreatment similarly enhanced antitumor
activity with either ABX or taxol in SPARC-negative tumors.
Key Words: nab-paclitaxel, Cremophor-solubilized paclitaxel,
SPARC, 5-aza-2-deoxycytidine, Non-small cell lung cancer (NSCLC).
(J Thorac Oncol. 2011;6: 998–1005)
Secreted protein acidic and rich in cysteine (SPARC)/osteonectin is a nonstructural matricellular calcium-binding
glycoprotein. SPARC is involved in physiological cell-matrix
interactions such as cell migration, angiogenesis, and tissue
remodeling. It is expressed in numerous malignancies such as
gastric, colorectal, and head and neck (H and N) cancers.1,2
SPARC expression is thought to facilitate drug distribution in
tumors and enhance clinical effectiveness of nanoparticle albu-
min-bound paclitaxel (nab-paclitaxel, abraxane, designated
ABX in this article) because of SPARC-binding characteristics
of albumin.3–7 ABXwas developed to avoid cremophor/ethanol-
associated toxicities associated with the parent compound (cre-
mophor-solubilized paclitaxel designated as taxol in this article).
Moreover, nanoparticle albumin-bound chemotherapy provides
a new paradigm for breaching the blood-stroma barrier to reach
the tumor cell, by targeting a previously unrecognized tumor-
activated albumin-specific biologic pathway with a nanoshell of
the human blood protein albumin. This nanoshuttle system
activates an albumin-specific (Gp60) receptor-mediated transcy-
tosis path through the cell wall of proliferating tumor endothelial
cells using caveolin 1 activated caveolar transport.8 Once in the
stromal microenvironment, the albumin-bound drug is preferen-
tially localized by a second albumin-specific binding protein
SPARC, secreted into the stroma by tumor cells. The resulting
collapse of stroma surrounding the tumor cell enhances the
delivery of the nab-chemotherapeutic to the tumor cell itself.
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ABX, a nanoparticle form of paclitaxel, is the first clinical
example of this nab-driven chemotherapy platform.
SPARC expression seemed to be correlated with antitu-
mor response to ABX in patients with H and N cancer, with
SPARC overexpression as determined by immunohistochemis-
try (IHC) leading to improved response to ABX in tumor
models. A study of intraarterial ABX showed a high overall
response rate of 78% in 54 patients with H and N cancer.9
Further characterization of the tumors from responders showed
that 91% of patients with H and N cancer responding to ABX
had SPARC-positive tumors. SPARC-negative patients exhib-
ited significantly lower response rate of 25% versus the overall
response rate of 75% (all patients, SPARC positive and nega-
tive). The SPARC-positive tumors had a response rate of 83%.10
In an in vivo tumor model, stable SPARC-overexpressing lines
of PC3 prostate cancer xenograft exhibited enhanced response to
ABX relative to wild type (WT) PC3.11 These lend support to
the hypothesis that SPARC expression in tumor tissues can
correlate with drug response, and this information can be used to
select the appropriate patient population.
In non-small cell lung cancer (NSCLC), SPARC is found
to be strongly expressed by IHC in peritumoral stromal fibro-
blasts.12 Strong SPARC expression was found in approximately
70% of cases. Although SPARC-expressing cancer cells can be
found located adjacent to necrotic areas, SPARC expression in
cancer cells per se was typically rare. Gazdar and coworkers13
demonstrated the lack of SPARC expression in 83% of NSCLC
cell lines. Aberrant methylation was found in 75% of NSCLC
cell lines with restoration of SPARC expression after treatment
with the demethylating agent 5-Aza-2-deoxycytidine (DEC).
Methylation of SPARC gene occurred in 65% of primary lung
cancer, resulting in loss of or weak SPARC protein expression in
tumor cells by IHC. In a multivariate Cox’s proportional hazard
model, promoter methylation of SPARC was found to be an
independent adverse prognostic factor next to tumor stage in
adenocarcinoma cases.
The aim of this study is to investigate whether there is
a correlation between tumoral SPARC expression and treat-
ment response to ABX in NSCLC in comparison with taxol.
That the mechanism of suppression of SPARC expression in
NSCLC is largely mediated by promoter region methylation
is relevant as there are demethylating agents available for
clinical use that may potentially increase SPARC expression.
We, thus, also aim to evaluate the hypothesis that SPARC
reexpression in tumor by pretreatment with a demethylating
agent DEC will result in improved efficacy of ABX in NSCLC
cell lines and primary tumor with low or absent SPARC expres-
sion because of promoter gene hypermethylation.
MATERIALS AND METHODS
Cell Lines and Minimally Passaged (Fewer than
10 Passages) Primary Patient-Derived Tumor
Specimen
NSCLC cell lines (H226, H358, H441, H522, H661,
H727, H1299, H1650, H1703, H2935, H460, H157, and
A549) were purchased from American Type Culture Collection
(Manassas, VA) and maintained in Roswell Park Memorial
Institute medium 1640 with 10% fetal bovine serum (Sigma, St
Louis, MO), 100 units/ml penicillin, and 100 g/ml streptomy-
cin (Cellgro, Manassas, VA) at 37°C in 5% CO2.
All patient-derived (PD) NSCLC tumor specimens
were derived from patients whose surgeries were performed
at Roswell Park Cancer Institute (RPCI; Buffalo, NY). Spec-
imens were processed through the Tissue Procurement Facil-
ity for pathologic assessment. Surgical samples were ob-
tained with informed consent from patients and under a
research protocol approved by the institutional review board
and the research ethics committee at RPCI. Samples were
examined for presence of malignant/normal areas before
transplantation into animals. Animal experiments were ap-
proved by the Institutional Animal Care and Use Committee.
Reagents and Drug Treatment with NSCLC
Cell Lines In Vitro
ABX was obtained from Abraxis BioScience (Phoenix,
AZ). Taxol was purchased from Ben Venue Labs (Bedford,
OH). DEC was purchased from Sigma-Aldrich (St. Louis, MO).
All the drugs were prepared and aliquoted and stored at 80°C
for use within 1 week. For DEC experiments with NSCLC cell
lines in vitro, cells were cultured in medium with DEC (5 M)
for 5 days, with medium changes on days 1 and 3. Either ABX
or taxol was added to the changed media on day 3. Control cells
were only treated with vehicle of 1‰ DMSO in 1 ml of media.
Cells were harvested for RNA extraction, SPARC expression
analysis, or cell death rate assessment on day 5.
Experiments with Tumor Xenografts In Vivo
Experimental studies were carried out using 6- to
8-week-old CB.17 severe combined immunodeficiency
(SCID)/SCID with an average body weight 25 g. H460
(5  106 cells) or PD NSCLC xenografts (mouse-to-mouse
passage), which were cut into small fragments (2–3 mm in
size), were implanted subcutaneously at the flank region.
Tumor growth was monitored by periodic visual inspection at
the site of implantation, and the dimensions of the xenografts
were measured every 2 to 3 days. Tumor volume was
calculated using the following formula: V  LD 
(SD)2/2, where V is the tumor volume, LD is the longest
tumor diameter, and SD is the shortest tumor diameter.
To establish a maximally tolerated dose to be used in
experiments involving pretreatment with DEC, groups of
mice implanted with H460 cell lines were tested at four dose
levels of DEC, i.e., 0.75, 1.5, 2, and 4 mg/kg, administered
intraperitoneally as a single dose and monitored for viability
(weight loss and death). Two mice from each group were
killed 48 hours after completing DEC treatment alone and
tumor xenografts harvested to affirm SPARC-expression sta-
tus. For combination drug treatment, ABX was administered
by tail vein injection at 30 mg/kg/d for 5 consecutive days.
Taxol and DEC were used at 13.4 mg/kg/d and 1.5 mg/kg/d,
respectively. The doses for ABX and taxol have been previ-
ously demonstrated to be equitoxic at these levels.5 At the end
of drug treatment, the mice were killed. Xenografts were
harvested and assayed to determine SPARC status. All mice
experimental protocols were approved by the Institutional
Animal Care and Use Committee of RPCI.
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Real-Time Polymerase Chain Reaction
Total RNA was extracted from the samples with Trizol
reagent (Invitrogen; Carlsbad, CA), and first-strand comple-
mentary DNA was generated using SuperScript III First-
Strand Synthesis System (Invitrogen). The forward polymer-
ase chain reaction (PCR) amplification primer of SPARC was
5-AAGATCCATGAGAATGAGAAG-3 (Ex8-S), and the
reverse primer was 5-AAAAGCGGGTGGTGCAATG-3
(Ex9-AS). Semiquantitative PCR was carried out for 4 min-
utes at 95°C for initial denaturation, followed by 33 cycles of
94°C for 25 seconds, 56°C for 25 seconds, and 68°C for 40
seconds. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as endogenous control. Quantitative real-time (RT)
PCR was done with SYBR GreenER qPCR superMix for ABI
PRISM (Invitrogen) using ABI 7300 RT PCR system (Invit-
rogen), and GAPDH was used as a housekeeping gene for
purpose of normalization.
DNA Extraction and Methylation-Specific PCR
Genomic DNA was obtained from cell lines and primary
tumors by using DNeasy Blood and Tissue Kit (Qiagen; Valen-
cia, CA) according to the manufacturer’s handbook. The DNA
methylation pattern in the CpG island of SPARCwas determined
using the method of methylation-specific PCR (MSP) and done
with EZ DNA Methylation Kit (Zymo research, Irvine, CA).




(sense), and sparc-msp-R: 5-AACGACGTAAACGAAAA-
TATCG-3 (antisense). PCR amplification was carried out
with bisulfite-treated DNA as a template using specific primer
sequences for the methylated and unmethylated status of the
gene. Water blanks were included with each assay. PCR
amplification was carried out for 12 minutes at 94°C for
initial denaturation, followed by 40 cycles of 94°C for 30
seconds, 58°C for 25 seconds, and 68°C for 45 seconds.
Results were confirmed by repeating the bisulfite treatment
and MSP for all samples.
Antibodies and Western Blot
Polyclonal antihuman SPARC antibody was purchased
from R&D System (Minneapolis, MN). Western blot analysis
was carried out as the standard method. Xenograft lysates
were prepared and subjected to immunoblot analysis using 50
g of cellular protein as described previously.14 The levels of
-actin (Sigma) were measured as control for equal loading.
Immunoblots were developed with enhanced chemilumines-
cence (Amersham Bioscience, Golden Valley, MN).
Cell Death Rate analysis
NSCLC cells were seeded into 24-well plates and
treated with DMSO or agents. Then cells were harvested and
stained with trypan blue and viewed under light microscope.
Treated cells were harvested and resuspended in trypan blue/
phosphate-buffered saline solution. The number of dead/
nonviable cells (blue cells) and viable cells (white cells) were
counted in representative randomly selected regions, and the
ratio of blue cells to white cells is calculated as the cell death
rate (%). Each experiment was performed in triplicate at least
three times.
Statistical Analysis
Data from in vitro studies are expressed as the mean
and standard deviation representing results from at least three
independent experiments using cells derived from separate
batches of cultures. To describe the observed variability in
the in vivo data and test for differences between groups, a
multivariate linear model was fit to each dependent variable
(tumor volume). All tests were two sided and tested at a 0.05
nominal significance level. SAS version 9.2 statistical soft-
ware (Cary, NC) was used for all statistical analyses. Differ-
ence was considered statistically significant when the calcu-
lated p value was less than 0.05.
RESULTS
SPARC Expression and Methylation Status in
NSCLC Cell Lines and PD NSCLC Primary
Tumors
To evaluate the expression of SPARC in NSCLC cell
lines and PD NSCLC specimen, SPARC expression was
examined by RT PCR in 13 NSCLC cell lines and 22 PD
NSCLC tumor xenografts. Specimens are considered SPARC
positive when SPARC expression is 75% or more relative to
the expression of the endogenous control, GAPDH. Speci-
mens are considered as SPARC negative if SPARC expres-
sion is less than 25% to the expression of GAPDH. Levels
in-between are considered SPARC intermediate. As shown in
Table 1, 8 of 13 (62%) NSCLC cell lines were SPARC
negative relative to the expression of internal control
GAPDH. Four of 13 (31%) NSCLC cell lines were SPARC
positive. For the 22 PD NSCLC xenografts, 15 of them (68%)
were SPARC negative; two were SPARC intermediate. The
others are SPARC positive. This is concordant with the
previous report.13
Tumoral SPARC Reexpression with
Demethylating Agent
DNA methylation in gene promoter region is the main
mechanism to silence gene expression. The loss of SPARC
expression in a large proportion of NSCLC specimens may be
due to the methylation in the promoter region of SPARC
gene. To verify this hypothesis, representative samples of
NSCLC cell lines or PD xenografts were analyzed. H226, a
SPARC-positive cell line, has the highest relative SPARC
expression ratio to endogenous control GAPDH (4.469, Table
1). MSP results showed that there was no methylation de-
tected within its promoter (Figure 1). H460, a SPARC-
negative cell line (Table 1), is methylated in SPARC promoter
region, and there is weak PCR signal with the unmethylated
promoter region. On treatment with DEC, the SPARC expres-
sion is up-regulated. This is shown as the increase of unmeth-
ylated promoter of SPARC in H460 (Figure 1), which man-
ifested as the upregulation of SPARC protein (Figure 2A).
Similar results were also observed in vitro with NSCLC cell
lines (A549, H460, and H157) and in vivo with PD xeno-
grafts (NSCLC_16325 and NSCLC_16384) and H460 xeno-
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TABLE 1. SPARC Expression Status Analysis in NSCLC Cell Lines and Patient-Derived Primary NSCLC Xenografts







H157 SPARC Target 21.85 0.67 1.591073 Positive
GAPDH ENDO 22.52
H226 SPARC Target 19.56 2.16 4.469149 Positive
GAPDH ENDO 21.72
H358 SPARC Target 33.03 10.28 0.000804 Negative
GAPDH ENDO 22.75
H441 SPARC Target 35.43 11.79 0.000282 Negative
GAPDH ENDO 23.64
H460 SPARC Target 34.21 11.07 0.000465 Negative
GAPDH ENDO 23.14
H522 SPARC Target 32.11 6.6 0.010309 Negative
GAPDH ENDO 25.51
H661 SPARC Target 22.79 1.29 2.445281 Positive
GAPDH ENDO 24.08
H727 SPARC Target 31.39 7.82 0.004425 Negative
GAPDH ENDO 23.57
H1299 SPARC Target 29.06 7.83 0.004395 Negative
GAPDH ENDO 21.23
H1650 SPARC Target 21.6 0.25 1.189207 Positive
GAPDH ENDO 21.85
H1703 SPARC Target 33.11 12 0.000244 Negative
GAPDH ENDO 21.11
H2935 SPARC Target 26.22 1.77 0.293209 Intermediate
GAPDH ENDO 24.45
A549 SPARC Target 33.41 12.36 0.00019 Negative
GAPDH ENDO 21.06
NSCLC_16384 SPARC Target n/a n/d n/d Negative
GAPDH ENDO 26.69
NSCLC_16325 SPARC Target n/a n/d n/d Negative
GAPDH ENDO 25.17
NSCLC_17265 SPARC Target 31.45 0.49 0.712025 Intermediate
GAPDH ENDO 30.96
NSCLC_16947 SPARC Target n/a n/d n/d Negative
GAPDH ENDO 27.36
NSCLC_17228 SPARC Target 22.58 3.46 11.00433 Positive
GAPDH ENDO 26.05
NSCLC_17291 SPARC Target 23.43 0.38 0.768438 Positive
GAPDH ENDO 23.05
NSCLC_17246 SPARC Target 24.45 2.64 6.233317 Positive
GAPDH ENDO 27.08
NSCLC_16898 SPARC Target 31.2 4.89 0.033726 Negative
GAPDH ENDO 26.31
NSCLC_17531 SPARC Target 24.54 0.19 1.140764 Positive
GAPDH ENDO 24.73
NSCLC_16591 SPARC Target 40 3.75 0.074325 Negative
GAPDH ENDO 36.25
NSCLC_16372 SPARC Target 30.84 0.04 0.972655 Positive
GAPDH ENDO 30.8
NSCLC_15848 SPARC Target 40 7.6 0.005154 Negative
GAPDH ENDO 32.4
NSCLC_16465 SPARC Target 40 9.19 0.001712 Negative
GAPDH ENDO 30.81
NSCLC_15946 SPARC Target 34.82 1.88 0.271684 Intermediate
GAPDH ENDO 32.94
(Continued)
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graft (Figures 1 and 2). The loss of SPARC expression in
NSCLC specimens is largely attributed to the methylation in
the promoter region of SPARC gene. Our results show that
SPARC expression can be up-regulated by exposure to DEC
in vitro or in vivo.
Endogenous Tumor SPARC Expression and
Response to ABX In Vivo
SPARC expression in tumor has been shown to facili-
tate the transport of albumin-bound drugs.11 ABX is an
albumin-bound paclitaxel. We, thus, sought to compare the
antitumor efficacy of ABX with equitoxic dose of taxol in a
series of PD NSCLC xenografts with different SPARC ex-
pression status. NSCLC_16372 is a SPARC-positive tumor.
As shown in Figure 3A, the growth of NSCLC_16372 xeno-
graft was suppressed on treatment with either taxol and ABX
compared with vehicle control. Nevertheless, ABX was more
effective than taxol in inhibiting xenograft growth (p 
0.0239). Similar results were observed in NSCLC_15946, a
SPARC-intermediate specimen. The tumor growth was sig-
nificantly inhibited with either taxol (p  0.0004) or ABX
(p 0.0001) compared with vehicle control. Again, exposure
to ABX displayed a more profound growth suppression than
taxol (p  0.0001; Figure 3B). NSCLC_16465 and
NSCLC_16591 are SPARC-negative tumors. Administration
of neither taxol nor ABX showed any effect on tumor growth
compared with vehicle control in NSCLC_16,591 (p 
0.3628 of taxol to vehicle; p  0.1826 of ABX to vehicle;
TABLE 1. (Continued)







NSCLC xenograft 1 SPARC Target 40 8.84 0.002182 Negative
GAPDH ENDO 31.16
NSCLC xenograft 2 SPARC Target 38.87 6.54 0.010746 Negative
GAPDH ENDO 32.33
NSCLC xenograft 3 SPARC Target 40 8.36 0.003044 Negative
GAPDH ENDO 31.64
NSCLC xenograft 4 SPARC Target 40 6.2 0.013602 Negative
GAPDH ENDO 33.8
NSCLC xenograft 5 SPARC Target 40 9.88 0.001061 Negative
GAPDH ENDO 30.12
NSCLC xenograft 6 SPARC Target 40 7.64 0.005013 Negative
GAPDH ENDO 32.36
NSCLC xenograft 7 SPARC Target 40 5.73 0.018841 Negative
GAPDH ENDO 34.27
NSCLC xenograft 8 SPARC Target 40 8.39 0.002981 Negative
GAPDH ENDO 31.61
SPARC, secreted protein acidic and rich in cysteine; NSCLC, non-small cell lung cancer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ENDO, endogenous control;
NA, not applicable.
FIGURE 1. Representative examples of methylation-specific
PCR assay for SPARC in NSCLC cell lines and NSCLC xeno-
grafts. H460 cells were treated with DEC (5 M) in vitro for
3 days. PCR products were visualized on 1.5% agarose gels.
w/, treated with; Me, methylated; UM, unmethylated; PCR,
polymerase chain reaction; SPARC, secreted protein acidic
and rich in cysteine; NSCLC, non-small cell lung cancer;
DEC, 5-Aza-2-deoxycytidine.
FIGURE 2. Western blot showing that SPARC expression in
xenografts and NSCLC cell lines is up-regulated on treat-
ment with DEC. A, NSCLC cell lines A549, H460, and H157
were treated with 5 M DEC for 3 days in vitro and then
harvested for RT-PCR. B, PD NSCLC xenografts and H460
xenografts treated with or without DEC 1.5 mg/kg/d, and
xenografts were harvested for SPARC expression analysis.
GAPDH were used as the endogenous control. w/, treated
with; SPARC, secreted protein acidic and rich in cysteine; PD
NSCLC, patient-derived non-small cell lung cancer; DEC,
5-Aza-2-deoxycytidine; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; RT-PCR, real-time polymerase chain reac-
tion.
Shao et al. Journal of Thoracic Oncology • Volume 6, Number 6, June 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1002
Figure 3D). Interestingly, in NSCLC_16465 xenografts,
ABX demonstrated significantly greater antitumor effect
compared with taxol (p  0.0001), which showed no differ-
ence compared with vehicle control. ABX is, thus, generally
more effective than taxol at equitoxic doses in inhibiting the
growth of PD NSCLC xenografts, and this effect is not
consistently correlated with tumor SPARC expression status.
Tumor SPARC Reexpression/Upregulation and
Response to ABX or Taxol
Our data indicated that SPARC expression was up-
regulated on treatment with DEC in vitro and in vivo. To
establish a tolerable dose to be used in experiments in vivo,
groups of mice implanted with H460 cell lines were tested at
four dose levels of DEC, i.e., 0.75, 1.5, 2, and 4 mg/kg,
respectively. This is based on prior publication showing that
DEC administered twice daily intraperitoneally for 5 days
was toxic at 10 mg/kg/dose, and 2 mg/kg dose was associated
with mild toxicity.15 There is dose-dependent reexpression of
SPARC in H460 xenografts on treatment with DEC. Never-
theless, DEC at 2 and 4 mg/kg was toxic with 6/8 (75%) mice
dead between 8 and 12 days after only one DEC dose
(without ABX treatment). DEC dose at 1.5 mg/kg was sub-
sequently used in the combination experiments.
To further elucidate the effect of SPARC expression
status on the differential antitumor efficacy of ABX in com-
parison with equitoxic dose of taxol in vivo, experiments
in two SPARC-negative PD NSCLC primary xenografts
(NSCLC_16325 or NSCLC_16384) and one SPARC nega-
tive established NSCLC cell line (H460) were performed.
First, SPARC expression in xenografts was up-regulated on
exposure to DEC (1.5 mg/kg; Figure 2B). Second, compared
with vehicle, on treatment with either ABX or taxol alone,
only administration with ABX in NSCLC_16325 showed
significant antitumor efficacy (p  0.0065). There was, how-
ever, no significant difference between ABX compared with
taxol in suppressing the growth of these SPARC-negative PD
xenografts (p  0.4577 in NSCLC_16325 and p  0.9897 of
NSCLC_16384; Figures 4A, B). Third, we found that the
antitumor activities of both taxol and ABX were enhanced to
a similar degree by pretreatment with DEC; however, this
seeming additive activity did not reach statistical significance
(p  0.1374 of ABX  DEC versus ABX and p  0.4713 of
taxol  DEC versus taxol in 16,325; p  0.8844 of ABX 
DEC versus ABX and p  0.7410 of taxol  DEC versus
FIGURE 3. Efficacy of ABX compared with taxol in PD
NSCLC xenografts. SCID mice bearing SPARC-positive
xenografts (NSCLC_16372) (A), SPARC-intermediate xeno-
grafts (NSCLC_15946) (B), or SPARC-negative xenografts,
NSCLC_16465 (C) and NSCLC_16591 (D), were treated
with vehicle, equitoxic dose of taxol (13.4 mg/kg), or ABX
(30 mg/kg). The overall antitumor efficacy of drugs was
measured as tumor volumes every 2 to 3 days. The error
bars represented the standard error of the mean. PD
NSCLC, patient-derived non-small cell lung cancer; SCID,
severe combined immunodeficiency; SPARC, secreted pro-
tein acidic and rich in cysteine.
FIGURE 4. Enhanced antitumor efficacy of taxol and ABX
by pretreatment with DEC in SPARC-negative xenografts.
A–C, SCID mice bearing SPARC-negative xenografts,
NSCLC_16325 (A), NSCLC_16384 (B), or H460 (C), were
administered with DEC (1.5 mg/kg), taxol (13.4 mg/kg) or
ABX (30 mg/kg) alone or the combination of DEC and taxol
or DEC and ABX. The overall antitumor efficacy of drugs was
measured as tumor volumes every 2 to 3 days. The error
bars represented the standard error of the mean. DEC,
5-Aza-2-deoxycytidine; SPARC, secreted protein acidic and
rich in cysteine; NSCLC, non-small cell lung cancer.
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taxol in 16,384; Figures 4A, B). Finally, in H460 xenografts,
ABX showed superior growth-suppressing activity compared
with vehicle or taxol (p  0.0002). Nevertheless, DEC
pretreatment resulted in minimal change to ABX antitumor
activity, whereas a synergistic effect was seen in combination
with taxol (p  0.0097). Nonetheless, the tumor growth
inhibition achieved by ABX alone seemed greater compared
with DEC with equitoxic dose of taxol, though not statisti-
cally significant (84% of ABX versus 66% of DEC  taxol,
p  0.5402) (Figure 4C).
Pretreatment with DEC to enhance antitumor efficacy
of taxol or ABX was also verified in SPARC-negative
NSCLC cell lines A549 and H460 in vitro. As shown in
Figure 5, DEC enhanced the cytotoxicity of both taxol and
ABX in a wide range of doses (2.5, 5, 10, 20, and 50 nM).
There is no obvious difference in the antitumor activity
between taxol and ABX at equimolar doses.
DISCUSSION
The role of SPARC in tumor development seemed to be
tumor-type dependent. In H and N cancer, glioma, and
melanoma, increased expression of SPARC is correlated with
tumor growth and poor survival in these patients.16–18 Nev-
ertheless, in NSCLC, colon cancer, and ovarian cancer, the
expression of SPARC is usually repressed by hypermethyl-
ation in its promoter region, which is related to poor patient
outcome, with induction of its expression exhibiting antipro-
liferative effect in some models.13,19,20 In our study, we
affirmed prior results from other investigators that SPARC
expression is weak or absent in majority of NSCLC tumors
and that a primary mechanism for this is mediated by pro-
moter methylation. These findings are relevant as there are
demethylating agents available for clinical use, and there are
data suggesting that ABX is an agent that may potentially be
targeted toward tumors that over-express SPARC.
To elucidate the role of SPARC status with respect to
the antitumor efficacy of ABX specifically in NSCLC, we
compared the effect of ABX and taxol in inhibiting tumor
growth of SPARC intermediate to positive PD xenografts in
vivo. Our data suggest that at equitoxic doses, ABX seems to
result in better antitumor response in this subgroup, support-
ing the initial hypothesis of SPARC expression as a bio-
marker comparative efficacy between ABX and taxol. These
results are compatible with the findings of markedly im-
proved tumor response to ABX in patients with H and N
cancer whose tumors overexpress SPARC.9,10 Moreover, the
effect is sustained, and mice in this group treated with ABX
had longer viability compared with either taxol or vehicle.
Interestingly, further experiments reveal that ABX also
showed superior antitumor activity compared with equitoxic
dose of taxol in some SPARC-negative NSCLC cells as well.
Although -tubulin III overexpression has been implicated in
taxane resistance, the -tubulin III expression profile in our
PD xenografts does not support correlation with sensitivity or
resistance to ABX or taxol in our results (experiment not
shown).
We also demonstrated that DEC up-regulated the ex-
pression of SPARC in established NSCLC cell lines and in
PD primary tumor xenografts both in vitro and in vivo.
Contrary to what is expected, our in vitro data showed that
additive antitumor efficacy can be seen in vitro to a similar
degree with either ABX or taxol at equimolar doses on
pretreatment with DEC at a variety of dose combinations.
This is somewhat recapitulated in the in vivo experiments
done in PD xenografts wherein the antitumor activity of
equitoxic doses of taxol and ABX were both enhanced on
pretreatment with DEC to a similar magnitude as well. This
is not surprising as the effect of DEC as a demethylating
agent can lead to broad changes in expression patterns of
various genes apart from SPARC. Moreover, there are other
factors that can mediate taxane sensitivity, and the results
seen with H460 xenografts and in one of the SPARC-negative
xenografts (NSCLC_16465) may simply reflect dose re-
sponse to higher molar dose of ABX when it is equitoxic to
taxol in tumors that are innately taxane sensitive. SPARC
expression in murine peritumoral tissue may have also con-
FIGURE 5. Cell death rate analysis with
NSCLC cell lines A549 and H460 in vitro show-
ing additive antitumor activity of ABX or taxol
by pretreatment with DEC. A and C, results of
H460 cells treated with escalating concentra-
tions of ABX or taxol after DEC 5M pretreat-
ment. B and D, results of A549 cells treated
with escalating concentrations of ABX or taxol
after DEC 5 M pretreatment. Treated cells
were harvested for cell death rates assay (*p 
0.05, compared with ABX or taxol treatment
alone). Data represents mean  standard devi-
ation of three independent experiments.
NSCLC, non-small cell lung cancer; DEC,
5-Aza-2-deoxycytidine.
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tributed to greater ABX activity in some SPARC-negative
xenograft experiments. This may also explain the significant
antitumor response to ABX alone in H460 xenograft, which
would have rendered superfluous any possible contributory
effect of DEC otherwise at the ABX dose used for this
experiment. Our results thus suggest that the effect of DEC
on other proteins may result in additive effects with either
ABX or taxol through non-SPARC mechanisms. Given the
fact that DEC is FDA-approved drug and ABX is also widely
used clinically, the combination treatment of DEC and ABX
may be a promising therapeutic strategy for NSCLC.
We acknowledge that our study is limited by the small
sample size of unique PD xenografts that were tested. Our
experiments were hampered by the protracted time required
for establishing the xenografts and lack of growth (i.e.,
xenografts unable to be established) for certain samples. As
indicated earlier, whether SPARC expression in the murine
peritumoral tissue could have contributed to the effects seen
in the experiments conducted in SPARC-negative tumor
samples is not known. Nonetheless, our study showed that a
superior antitumor response to ABX relative to equitoxic
dose of taxol in PD NSCLC xenografts can be seen in both
SPARC-expressing tumors and some SPARC-negative tu-
mors. Additive effects with decitabine pretreatment, using
either taxol or ABX are likely mediated by non-SPARC
mechanisms. These results need to be verified in a study
involving larger numbers of patient samples.
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